血流储备分数指导PCI与冠状动脉旁路移植术治疗三支血管病变:FAME 3试验3年随访
FAME 3试验随机纳入1500例三支血管病变(非左主干)患者,比较FFR指导的PCI(使用佐他莫司药物洗脱支架)与CABG。3年随访显示,死亡、心肌梗死或卒中的复合终点发生率两组无显著差异(12.0% vs 9.2%;HR 1.3,95%CI 0.98-1.83;P=0.07),但PCI组心肌梗死发生率更高(7.0% vs 4.2%;HR 1.7,95%CI 1.1-2.7;P=0.02),死亡和卒中无差异。
要点
- FFR指导PCI与CABG的3年死亡、心梗或卒中复合终点无显著差异。
- PCI组心肌梗死发生率显著高于CABG组(7.0% vs 4.2%)。
- 两组死亡和卒中发生率无显著差异。
核心结论
- 3年随访时,FFR指导的PCI使用当代药物洗脱支架与CABG相比,死亡、心肌梗死或卒中的复合终点发生率无显著差异。
- PCI组心肌梗死发生率高于CABG组,而死亡和卒中发生率无差异。
研究设计与样本
- FAME 3为研究者发起的国际多中心随机试验,纳入48个中心的三支血管病变(非左主干)患者。
- 共1500例患者随机接受FFR指导的PCI(佐他莫司药物洗脱支架)或CABG,随访率>96%。
主要发现
- 3年死亡、心肌梗死或卒中复合终点发生率:PCI组12.0%,CABG组9.2%(HR 1.3,95%CI 0.98-1.83;P=0.07)。
- 死亡发生率:PCI组4.1%,CABG组3.9%(HR 1.0,95%CI 0.6-1.7;P=0.88)。
- 卒中发生率:PCI组1.6%,CABG组2.0%(HR 0.8,95%CI 0.4-1.7;P=0.56)。
- 心肌梗死发生率:PCI组7.0%,CABG组4.2%(HR 1.7,95%CI 1.1-2.7;P=0.02)。
临床怎么用
- 对于三支血管病变(非左主干)患者,FFR指导的PCI使用当代药物洗脱支架可作为CABG的替代选择,需权衡心肌梗死风险。
- 3年随访数据可用于医患共同决策,讨论血运重建策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Previous studies comparing percutaneous coronary intervention (PCI) with coronary artery bypass grafting (CABG) in patients with multivessel coronary disease not involving the left main have shown significantly lower rates of death, myocardial infarction (MI), or stroke after CABG. These studies did not routinely use current-generation drug-eluting stents or fractional flow reserve (FFR) to guide PCI. METHODS: FAME 3 (Fractional Flow Reserve versus Angiography for Multivessel Evaluation) is an investigator-initiated, multicenter, international, randomized trial involving patients with 3-vessel coronary artery disease (not involving the left main coronary artery) in 48 centers worldwide. Patients were randomly assigned to receive FFR-guided PCI using zotarolimus drug-eluting stents or CABG. The prespecified key secondary end point of the trial reported here is the 3-year incidence of the composite of death, MI, or stroke. RESULTS: A total of 1500 patients were randomized to FFR-guided PCI or CABG. Follow-up was achieved in >96% of patients in both groups. There was no difference in the incidence of the composite of death, MI, or stroke after FFR-guided PCI compared with CABG (12.0% versus 9.2%; hazard ratio [HR], 1.3 [95% CI, 0.98-1.83]; P=0.07). The rates of death (4.1% versus 3.9%; HR, 1.0 [95% CI, 0.6-1.7]; P=0.88) and stroke (1.6% versus 2.0%; HR, 0.8 [95% CI, 0.4-1.7]; P=0.56) were not different. MI occurred more frequently after PCI (7.0% versus 4.2%; HR, 1.7 [95% CI, 1.1-2.7]; P=0.02). CONCLUSIONS: At 3-year follow-up, there was no difference in the incidence of the composite of death, MI, or stroke after FFR-guided PCI with current-generation drug-eluting stents compared with CABG. There was a higher incidence of MI after PCI compared with CABG, with no difference in death or stroke. These results provide contemporary data to allow improved shared decision-making between physicians and patients with 3-vessel coronary artery disease. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT02100722.
引用
- Zimmermann FM, Ding VY, Pijls NHJ, et al. Fractional Flow Reserve-Guided PCI or Coronary Bypass Surgery for 3-Vessel Coronary Artery Disease: 3-Year Follow-Up of the FAME 3 Trial. Circulation. 2023. PMID: 37602376. doi:10.1161/CIRCULATIONAHA.123.065770
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。